| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
This compound does not have a specific biological target; it functions as a chemical building block for peptide synthesis. As a glycine derivative, it is used to introduce N-allylglycine residues into peptides. The Fmoc group serves as a protective group in peptide synthesis, preventing side reactions and allowing selective removal under basic conditions. The allyl group introduces a reactive functionality that can be used for further modifications or crosslinking. It facilitates the synthesis of peptides with specific sequences and structures.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value lies in its chemical utility as a protected amino acid building block. Studies suggest that it may interact with specific receptors or enzymes, leading to the modulation of cellular signaling pathways, but these effects would be associated with the final peptide products, not the building block itself. It is primarily used as a research tool in peptide synthesis. |
| ln Vivo |
This compound is not administered in vivo as a therapeutic agent. It is a research chemical utilized as a building block in peptide synthesis. The final deprotected peptide product, not this protected intermediate, would be the subject of in vivo pharmacological testing for therapeutic efficacy and safety. The Fmoc-protected allylglycine derivative itself is never administered to animals as a test compound. It is a key building block in the synthesis of peptides.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to Fmoc-N-allylglycine as it is not a drug. Its use is in organic synthesis and peptide chemistry. A typical protocol involves its use as a building block in Fmoc SPPS, where the Fmoc group is removed with a base (e.g., piperidine) to allow for coupling with the next amino acid. The allyl group can be used for further modifications or crosslinking after peptide synthesis. It facilitates the synthesis of peptides with specific sequences and structures.
|
| Cell Assay |
This compound is not used in cell-based assays as a therapeutic agent. Its role is as a research chemical and building block for peptide synthesis. It is a white to off-white solid powder. Purity is typically ≥98%. The product is for research purposes only and is not intended for human or veterinary use. It is a key building block in the synthesis of peptides.
|
| Animal Protocol |
In vivo animal experiments do not involve Fmoc-N-allylglycine as a test article. It is a chemical intermediate used in the synthesis of peptide-based drug candidates. If used to synthesize a therapeutic peptide, that final product would be subjected to animal testing. The Fmoc-protected allylglycine derivative itself is not administered to animals as a therapeutic agent. It is a key building block in the synthesis of peptides.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Fmoc-N-allylglycine as it is not a drug. It is a small molecule (MW 337.37 g/mol) with the formula C20H19NO4. Its properties are relevant for chemical handling and storage rather than for systemic exposure studies. The Fmoc and allyl groups are designed for synthetic utility, not for bioavailability.
|
| Toxicity/Toxicokinetics |
The toxicity of Fmoc-N-allylglycine is not extensively documented, as it is a research chemical not intended for human or veterinary use. It should be handled with standard laboratory precautions, including the use of appropriate personal protective equipment and working in a well-ventilated area. The compound is a white to off-white solid powder at room temperature. It is not intended for diagnostic, therapeutic, or other medical applications.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
This compound is a glycine derivative with an Fmoc protecting group on the amino group and an allyl substituent on the nitrogen. The Fmoc group serves as a protective group in peptide synthesis, preventing side reactions and allowing selective removal under basic conditions. The allyl group introduces a reactive functionality that can be used for further modifications or crosslinking. It is a key building block in the synthesis of peptides, allowing researchers to create complex structures with specific functionalities. It is not a pharmaceutical.
|
| Molecular Formula |
C20H19NO4
|
|---|---|
| Molecular Weight |
337.37
|
| Exact Mass |
337.131
|
| CAS # |
222725-35-1
|
| PubChem CID |
10640670
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.508
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
25
|
| Complexity |
484
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CCN(CC(=O)O)C(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
| InChi Key |
NVNQGCMKCQZFSM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19NO4/c1-2-11-21(12-19(22)23)20(24)25-13-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h2-10,18H,1,11-13H2,(H,22,23)
|
| Chemical Name |
2-[9H-fluoren-9-ylmethoxycarbonyl(prop-2-enyl)amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9641 mL | 14.8205 mL | 29.6410 mL | |
| 5 mM | 0.5928 mL | 2.9641 mL | 5.9282 mL | |
| 10 mM | 0.2964 mL | 1.4821 mL | 2.9641 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
